Table 4.
T1 relaxometry for the assessment of liver disease.
| Study | Study design | Patients | Main findings |
|---|---|---|---|
| Smith et al., 1981 | HV vs. patients with diffuse liver disease | HV (n = 15) | Longer T1 in cirrhosis and CAH |
| Cirrhosis (n = 5) | |||
| CAH* (n = 1) | |||
| Doyle et al., 1982 | HV vs. patients with diffuse liver disease | HV (n = 12) | Longer T1 in cirrhosis |
| Cirrhosis (n = 10) | |||
| The Clinical NMR Group, 1987 | T1 vs. histology | Patients with suspected parenchymal disease (n = 55) | Tendency toward longer T1 in cirrhosis/hepatitis |
| Thomsen et al., 1990 | HV vs. disease controls vs. cirrhosis | HV (n = 7) | Longer T1 in cirrhosis |
| Disease controls (n = 17) | No association with histology | ||
| T1 vs. histology in a subset | |||
| Cirrhosis (n = 15) | |||
| Histology subset(n = 10) | |||
| Keevil et al., 1994 | HV vs. patients with diffuse liver disease | HV (n = 42) | Longer T1 in patients with cirrhosis and CAH |
| Liver disease (n = 44) | |||
| Heye et al., 2012 | HV vs. cirrhosis | HV (n = 31) | T1 longer in cirrhosis |
| Cirrhosis (n = 61) | |||
| Kim et al., 2012 | Non cirrhotic patients vs. CHB cirrhosis | Non cirrhotic patients (n = 92) | T1 shorter in cirrhosis |
| HBV cirrhosis (n = 87) | |||
| Cassinotto et al., 2015 | HV vs. cirrhosis | HV (n = 40) | T1 longer in cirrhosis |
| Cirrhosis (n = 89) | |||
| Hoad et al., 2015 | T1 vs. histology | Training cohort (n = 64) | AUROC for cirrhosis 0.92 |
| Validation cohort (n = 46) | |||
| AUROC for advanced fibrosis 0.81 |
HV, healthy volunteers; CAH, chronic active hepatitis; HBV, hepatitis B virus; AUROC, area under the receiver operating characteristic curve.
*
Chronic active hepatitis is a historical term used to describe a hepatitis of unknown etiology, now believed to be chronic hepatitis C and is no longer used in clinical practice.